MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Incyte

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
From Incyte
Via Business Wire
Tickers INCY
News headline image
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Executive Leadership Appointments
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Change to its Board of Directors
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story